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Abstract
Bile duct strictures are a common complication in patients with advanced chronic pancreatitis and have a variable clinical
presentation ranging from an incidental finding to overt jaundice and cholangitis. The diagnosis is mostly made during
investigations for abdominal pain but jaundice may be the initial clinical presentation. The jaundice is typically transient but
may be recurrent with a small risk of secondary biliary cirrhosis in longstanding cases. The management of a bile duct
stricture is conservative in patients in whom it is an incidental finding as the risk of secondary biliary cirrhosis is negligible.
Initial conservative treatment is advised in patients who present with jaundice as most will resolve once the acute on chronic
attack has subsided. A surgical biliary drainage is indicated when there is persistent jaundice for more than one month or if
complicated by secondary gallstones or cholangitis. The biliary drainage procedure of choice is a choledocho-jejunostomy
which may be combined with a pancreaticojejunostomy in patients who have associated pain. Since many patients with
chronic pancreatitis have an inflammatory mass in the head of the pancreas, a Frey procedure is indicated but a resection
should be performed when there is concern about a malignancy. Temporary endoscopic stenting is reserved for cholangitis
while an expandable metal stent may be indicated in patients with severe co-morbid disease.
Incidence
The incidence of common bile duct stricture (CBDS)
in chronic pancreatitis (CP) varies widely depending
on the precise definition, diagnostic vigor, and demo-
graphics of any given series. The wide variation in the
reported incidence, which ranges from 3% to 46%
[18] (Table I), occurs because not all patients with
biliary obstruction in CP present with jaundice. The
jaundice may frequently be transient [9], and in an
appreciable number of patients the bile duct stricture
is discovered incidentally [1014].
Pathogenesis
The anatomical relationship of the common bile duct
(CBD) with the head of the pancreas is an important
factor influencing the nature of the stenosis in CP. In up
to 85% of people, the CBD traverses the pancreatic
head and is adjacent posteriorly in the remainder [15].
The intrapancreatic portion of the CBD varies in
length from 1.5 to 6 cm, which accounts for the
variability of stricture lengths seen in clinical practice
[16].
CBDS occurs as a consequence of recurrent acute
inflammatory episodes which may ultimately result in
a periductal fibrotic stricture [10]. This occurs more
commonly in advanced CP, with the highest incidence
in the calcific variant [9,1721]. The development of
a pseudocyst may also be a contributing factor, but is
seldom the sole cause of a CBDS [2224]. Resolution
of the acute inflammatory process or a pseudocyst
often results in relief of the jaundice, but a residual
low-grade obstruction is common, as indicated by a
persistently raised alkaline phosphatase (ALP) or a
dilated CBD on ultrasonography. A pseudocyst, as the
dominant cause of jaundice, is only implicated when
this resolves with spontaneous resolution of the cyst or
after cyst drainage [25].
Clinical presentation
The clinical course of a CBDS varies, and is char-
acterized by exacerbations and remissions. Some
(Received 2 October 2007; accepted 26 October 2007)
ISSN 1365-182X print/ISSN 1477-2574 online # 2007 Taylor & Francis
DOI: 10.1080/13651820701774883
Correspondence: P. C. Bornman, Department of Surgery, University of Cape Town Health Sciences Faculty, Observatory 7925, Cape Town, South Africa.
Tel: 27 21 404 3042. Fax: 27 21 4478240. E-mail: philippus.bornman@uct.ac.za
HPB, 2007; 9: 421428
patients with biliary obstruction may be asymptomatic
and have only modestly deranged liver function tests.
This ‘‘incidental’’ presentation occurs in up to 17% of
patients [13]. Although pain is the predominant
clinical feature in most patients [2,3,8,13,26], it is
doubtful that a CBDS per se is a major contributing
factor. Jaundice is present in 30% [10] to 50% [13] of
patients, and may be transient, recurrent, or persistent
[26]. Transient jaundice is typically seen during acute
exacerbations and recedes with resolution of the
inflammatory process. Other biochemical markers of
biliary obstruction, such as ALP and GGT, are slower
to return to normal levels or may persist. Recurrent
jaundice occurs with repeated exacerbations and may
become persistent when associated with severe fibro-
sis and calcification. Cholangitis occurs in 10% of
patients [27,28] and varies from subclinical episodes
to overt septicemia [12]. Life-threatening cholangitis
is seldom the first indication of the diagnosis [12,29].
Although several studies have reported a significant
risk of development of secondary biliary cirrhosis
[1,2,6,30], other series have not confirmed this
finding [5,3133]. Frey et al. [28] found that the
average incidence of biliary cirrhosis associated with
CBDS was 7.3% (Table II) [1,2,5,6,9,14,3034], and
in four of the studies [5,3133] in their collected series
no patients had biliary cirrhosis.
Laboratory investigations
Elevation of the ALP is the most frequently encoun-
tered abnormal laboratory test [2] and a persistent
increase greater than 2-fold for more than 1 month
has been proposed as a specific marker of a CBDS
[11], although ALP levels may exceed 1000 IU.
Transient hyperbilirubinemia is typically seen in CP
and is the result of edema of the pancreas during an
acute exacerbation, but may become persistent when
there is established cicatrization of the distal CBD in
more severe forms of the disease [26,35].
Radiology
The demonstration of pancreatic calcification on a
plain abdominal roentgenogram may be the first clue
to the diagnosis. Ultrasonography will demonstrate
extrahepatic bile duct obstruction in 80% of cases
[36], but a CT scan (Figure 1) is usually required to
provide accurate delineation of the parenchymal and
Table II. Incidence of biliary cirrhosis in patients with common bile










Warshaw et al. [30] 1976 6 3 3
Scott [9] 1977 11 1 4
Bradley & Salam [31] 1977 13  2
Yadegar et al. [1] 1980 21 2 3
Afroudakis &
Kaplowitz [6]
1981 24 4 
Creaghe et al. [34] 1983 10 2 1
DaCunha et al. [32] 1984 24  3
Aranha et al. [5] 1984 51  3
Sugerman et al. [33] 1986 16  1
Stabile et al. [2] 1987 40 6 6
Stahl et al. [14] 1988 38 3 1
Total 288 21 (7.3%) 27







Yadegar et al. [1] 1980 651 21 3
Stabile et al. [2] 1987 910 40 4
Huizinga et al. [3] 1992 509 45 9
Petrozza & Dutta [4] 1985 151 15 10
Aranha et al. [5] 1984 1262 51 4
Afroudakis & Kaplowitz [6] 1981 300 24 8
Wisloff et al. [7] 1982 79 36 46
Sand & Nordback [8] 1995 77 18 23
Figure 1. CT scan showing chronic calcific pancreatitis. 1b. CT
scan showing pancreatic calcification and common bile duct
dilatation (arrow).
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ductal morphological changes of the pancreas, includ-
ing the presence of a pseudocyst [2,36]. Typically, a
smooth and tapering distal CBDS is seen on biliary
imaging [7,1012,30,35,37]. Occasionally, other
CBDS shapes, such as the ‘‘bent knee’’ and ‘‘hour-
glass’’ configurations have been described [7,10,12].
In an attempt to differentiate and characterize CBDS
secondary to CP from those due to other causes,
Caroli & Nora [38] classified the cholangiographic
appearance of bile duct strictures into five types
(Figure 2). Type I and type III are most commonly
seen in CP [39,40]. In 100 CP patients, Sarles &
Sahel [10] showed a 60% incidence of type I stricture;
a similar observation was made by Petrozza & Dutta
[4]. In the latter series of 15 cholangiograms, the
length of the strictured segment varied from 16 to 57
mm (mean 40.7 mm), while the maximal diameter of
the dilated portion of the CBD ranged from 13 to 28
mm (mean 18.9 mm). Snapes et al. noted a CBD
diameter ranging from 16 to 25 mm [37], and
postulated that even partial stenosis of the CBD
may elevate the biliary pressures sufficiently to dilate
the proximal biliary system over time. Petrozza &
Dutta [4] showed that a particular radiographic
configuration of the stricture was not helpful in
determining the nature of the underlying process,
and therefore predict its natural history. As diagnostic
investigations, ERCP (Figure 3a) and PTC have been
superseded to a large extent by multislice CT scan
and MRI/MRCP, which, in most instances, will
provide adequate imaging of the biliary and pancrea-
tic anatomy [41,42] (Figure 3b).
Cholestatic jaundice  carcinoma or
pancreatitis?
The differentiation from pancreatic cancer can be
difficult, particularly in patients with pre-existing CP.
Patients with alcohol-induced CP may be at higher
risk of pancreatic malignancy, but the evidence is
inconclusive. Lowenfels et al. [43] reported a 16-fold
increase in risk, while Karlson et al. [44] failed to
show any association in a Swedish Cohort study. The
Figure 2. Cholangiographic appearance of bile duct strictures (as identified by Caroli & Nora) [38]. Type I: Long retropancreatic stenosis.
Type II: Dilatation of the main bile duct, stricture of the sphincter of oddi. Type III: Hourglass stricture. Type IV: Symptomatic of either a
cyst (a), or a cancer (b and c). Type V: Cancer of the pancreas.
Figure 3. ERC demonstrating a smooth tapering biliary stricture in
a patient with chronic calcific pancreatitis. 3b. MRCP showing
dilated extrahepatic bile duct with smooth tapering stricture.
Chronic pancreatitis, bile duct stenosis, obstructive jaundice 423
entity of focal or segmental pancreatitis, which can be
associated with groove pancreatitis, may also mimic
carcinoma of the pancreas [45].
Warpnick et al. [46] devised a point score system to
differentiate CP from carcinoma which showed that
older patients with a higher and progressive rise in the
serum bilirubin were more likely to have a pancreatic
malignancy. A similar observation was made by Frey
et al. [28].
While CT scan provides good visualization of the
pancreas, differentiation between a carcinoma and CP
may be difficult in the absence of other findings, such
as metastases [47]. Cholangiographic features may be
unreliable because of a wide variability of the cholan-
giographic appearances of the stricture [14], but
complete obstruction is rare in CP. ERCP is still
more accurate than MRCP in delineating main
pancreatic and side duct morphology [11], which
may assist in the differential diagnosis.
CA 19-9 is useful in establishing the diagnosis of
pancreatic cancer [48], with a sensitivity of 80% to
85% and specificity of 85% to 90% [49,50]. Markedly
elevated levels greater than 1000 U/ml increase the
specificity for pancreatic cancer to 99% [49]. How-
ever, in patients with obstructive jaundice, elevated
biliary pressures result in an exaggerated leakage of
CA 19-9 into serum [51], with the resultant high
levels seen in the absence of malignancy. Thus, CA
19-9 may be elevated in CP with biliary obstruction,
although levels seldom exceed 100120 U/ml [51]. In
20 patients with CP, Gentiloni et al. [52] reported a
median CA 19-9 level of 30.4 U/ml with a range of 3
to 6123 U/ml. Other authors [53,54] have also
reported levels in excess of 2000 U/ml. Caution
should thus be exercised in the interpretation of CA
19-9 as a marker of differentiating carcinoma from
pancreatitis, especially in patients with biliary ob-
struction [54].
Other tumor markers, such as CA 494 [55],
pancreatic juice 90K [52], and pancreatic ductal cell
telomerase activity [56] have been investigated to
distinguish benign from malignant pancreatic disease,
but their applicability has so far been limited. Del
Maschio and co-workers [47] prospectively per-
formed CA 19-9 assays, CT scan, ultrasound, and
CT-guided fine needle aspiration biopsy of the pan-
creas in 81 consecutive patients with suspected CP or
pancreatic neoplasm. The CT-guided aspiration
yielded superior results with an accuracy of 94%.
Management
Management decisions are dictated largely by the
clinical presentation and the morphological changes
in the pancreas. Clinical factors to consider include
the presence and severity of associated pain, the
occurrence and duration of jaundice, and concern
about an underlying malignancy. Surgical strategy will
depend on whether there is an inflammatory mass in
the head of the pancreas and the degree of bile duct
and pancreatic duct dilatation.
The incidental finding of a CBDS with varying
degrees of bile duct dilatation on imaging with or
without a raised AP is well documented [1012]. This
particular group of patients may have either a normal
or more typically a disproportionately elevated serum
ALP level. The perceived risk of secondary biliary
cirrhosis, especially if the ALP is markedly elevated,
has prompted some authors to advocate prophylactic
biliary drainage in these patients [11,12]. While Frey
et al. [28] reported an overall incidence of 7.3% for
secondary biliary cirrhosis, other authors have not
noted this complication [5,13,3133]. When adopting
a conservative approach for asymptomatic or mini-
mally symptomatic patients during a follow-up period
of up to 4 years, Kalvaria et al. [13] found that no
patients developed secondary biliary cirrhosis. A
similar strategy and outcome has been reported by
other authors [7,10,14,16,26]. These patients should
therefore be treated conservatively and monitored
with 6-monthly liver function tests and biliary ultra-
sound. As there is no reliable means of predicting
progression to biliary cirrhosis, Yadegar and co-work-
ers [1] have recommended serial liver biopsies at 6
and 12 months. However, the low risk of developing
secondary cirrhosis in these patients does not justify
routine or repeated liver biopsies, which may be
difficult to interpret histologically. Similarly, the
placement of stents is strongly discouraged, as this
may cause secondary infections with clogging of the
stents.
A CBDS is a common finding during investigations
for pain in CP. Many authors concur that the pain is
more likely to be pancreatic in origin [1,2,5,33,34]
unless there are associated bile duct stones [13].
Although relief of pain after biliary diversion has
been reported [30], a conservative approach should
be adopted in the absence of associated jaundice [13].
In jaundiced patients, management will be deter-
mined whether jaundice is transient, recurrent, or
persistent [32]. A conservative approach is warranted
for transient jaundice, which is frequently self-limiting
due to resolution of edema or a pseudocyst in the
head [1,7,1012,14,26,31,57]. Spontaneous resolu-
tion of jaundice occurs within 1 month in 2050% of
patients [4,7,9,11,31]. Early biliary drainage is in-
dicated in the presence of choledocholithiasis and
cholangitis.
Biliary decompression is recommended when jaun-
dice persists for more than 1 month. The type of
biliary drainage depends on the patient’s fitness and
willingness to undergo surgery, the morphological
changes in the pancreatic head, the biliary and
pancreatic ductal systems, and the suspicion of
malignancy. Options for biliary drainage include
stenting and operative bypass.
Endoscopic biliary stenting has a high technical
success rate and provides short-term resolution of
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jaundice [58,59], but stent malfunctioning with clog-
ging and septic complications is common (Table III)
[5866]. Farnbacher et al. [58] analyzed 31 patients
following endoscopic plastic stent placement over a
mean duration of 10 months and found that although
the jaundice improved in all patients after insertion of
the stent, complete regression of stenosis occurred in
only 13%. Similar results were reported by Kahl et al.
[59], who in addition found that their patients with
pancreatic calcification did poorly with endoscopic
biliary stenting. This finding was confirmed by
Draganov et al. [67]. Deviere et al. [61] reported
migration of the stent in 10 patients (40%) and
blockage in 8 of 25 patients who were treated with a
biliary endoprosthesis. Clogging of the stent occurred
after a mean time of 6.5 months, and dislodgement 11
weeks after placement. Catalano and others [68],
however, showed better long-term results with place-
ment of multiple simultaneous biliary stents (45
stents per patient), even in the presence of calcifica-
tion. They concluded that endoscopic intervention
with multiple stents provided good long-term results
and may obviate the need for surgical procedures.
Nevertheless, close surveillance is important with
judicious replacement of stents either at planned
intervals or with early evidence of malfunctioning.
Although the role of self-expandable metal mesh
stents for malignant biliary obstruction is well estab-
lished [6972], its use in benign strictures, including
CP, is less clear and controversial. Deviere et al. [73]
prospectively followed 20 patients with self-expanding
metal stents for a mean period of 33 months. The
stents remained patent and functional in all but two
patients. They concluded that self-expanding metal
stents could become an effective alternative to surgical
biliary diversion. However, other smaller studies [74
77] have produced variable results, few of which could
confirm the encouraging results of Deviere [73].
Currently, stenting is at best a temporizing procedure,
particularly for cholangitis. As a definitive treatment,
stenting should be reserved for patients with serious
co-morbid disease or those unwilling to undergo
surgery. However, indications for stenting may ex-
pand with the emergence of removable expandable
[78,79] and bio-absorbable stents [8082].
In a major review, Frey et al. [28] listed seven
indications for surgical intervention for a CBDS in CP
(Table IV). The authors are in full agreement with
these proposed indications, except for the group of
patients with a persistently raised ALP 3 times normal
for more than 1 months. The choice of surgical
procedure depends on the clinical presentation (asso-
ciated pain or suspicion of malignancy), the presence
of an inflammatory mass in the head, and main
pancreatic duct anatomy. Careful radiological imaging
is required to plan surgical strategy [13,28]. In the
absence of pain, either a choledochoduodenostomy or
a Roux-en-Y choledochojejunostomy provides effec-
tive biliary drainage; these are the surgical procedures
of choice [5,13,16,2628,31,83]. While cholecystoje-
junostomy is easier to construct, it is a poor option, as
the long-term failure rate is up to 23% [27] and
compares unfavourably with choledochoduodenost-
omy and Roux-en-Y choledochojejunostomy, which
have failure rates of 2.5% and 2.1%, respectively.
While choledochoduodenostomy is a simpler proce-
dure [13,5,16,26,31], the reported higher incidence
of ‘‘sump syndrome’’ [3,84] favours Roux-en-Y cho-
ledochojejunostomy, particularly when an additional
pancreatic duct or pseudocyst drainage is required.
In the presence of jaundice and an inflammatory
mass, a modified Frey [85] operation is preferred.











Huibregtse et al. [60]* 1984 52  33 32
Deviere et al. [61] 1990 25 100 12 14
Barthet et al. [62] 1994 19 100 10 12
Smits et al. [63] 1996 58 100 28 46
Born et al. [64] 1998 18 100 17 23
Kiehne et al. [65] 2000 14 100 16 52
Vitale et al. [66] 2000 25 100 80 32
Farnbacher et al. [58] 2003 31 94 32 28
Kahl et al. [59] 2003 61 100 26 40
* After stent extraction.
Table IV. Indications for biliary drainage (Frey et al. [28])
1. Symptomatic cholangitis or infected bile.
2. Biliary cirrhosis (biopsy proven).
3. CBD stones in association with common bile duct stricture.
4. Inability to rule out cancer of the pancreas.
5. Progression of the common bile duct stricture based on
radiological assessment of increased dilatation of the
common and intrahepatic bile ducts.
6. Persistent jaundice for over a month.
7. Persistently elevated alkaline phosphatase
(3 normal levels 1 month).
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The coring out of the pancreatic head may decom-
press the intrapancreatic portion of the CBD [86], but
if there is any doubt, and in particular when the bile
duct is grossly dilated, it is advisable to add a side-to-
side Roux-en-Y choledochojejunostomy. An alterna-
tive to the Frey operation is the Beger duodenal
preserving resection of the head [87], but if there is
concern about malignancy it is strongly recommended
to proceed to standard or pylorus preserving pancrea-
tico-duodenectomy, which will avoid the risk of tumor
seeding.
Conclusion
CBDS associated with CP usually indicates advanced
disease and is mostly found with chronic calcific
pancreatitis. The natural history depends on the
severity of the fibrosis and calcification and the
frequency of the superimposed acute inflammatory
exacerbations. The clinical presentation varies from
an incidental discovery to persistent jaundice and,
more rarely, overt cholangitis. Minimally sympto-
matic patients should be treated conservatively with
careful monitoring of liver functions at 6-month
intervals (Figure 4). A conservative approach is also
recommended for patients who present with jaundice,
since this may resolve after resolution of an acute
inflammatory episode. Biliary intervention is indi-
cated when there is persistent jaundice for longer than
a month or when frequent relapses occur, thus
avoiding the risk of secondary biliary cirrhosis and
cholangitis.
The preferred surgical biliary drainage is a chole-
dochojejunostomy and in patients who also have pain
and an inflammatory mass in the head, the authors
prefer the addition of a Frey procedure. When there
is concern about an underlying malignancy, the





































Figure 4. Management algorithm: biliary obstruction in chronic pancreatitis.
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Biliary stenting should be restricted to patients who
present with overt cholangitis or patients who are
unfit for surgical intervention. In future, the role of
stenting as definitive treatment may be extended
with the development of removable expandable
stents.
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